LAUSR

Ophthalmol 94: e669. Chan EW, Eldeeb M, Dedhia CJ, Mansour A & Chhablani J (2017): One-year treatment outcomes of ziv-aflibercept for treatmentna€ıve macular oedema in branch retinal vein occlusion. Acta Ophthalmol [Epub ahead of print]. Chhablani J, Dedhia CJ, Peguda HK & Stewart M (2017): Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina [Epub ahead of print]. Heier JS, Brown DM, Chong V et al. (2012): Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119: 2537–2548. MansourAM, Chhablani J, Antonios RS, Yogi R, Younis MH, Dakroub R & Chahine H (2016): Three-month outcome of ziv-aflibercept for exudative age-relatedmacular degeneration. Br J Ophthalmol 100: 1629–1633. Oishi A, Kojima H, Mandai M et al. (2013): Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156: 644–651. de Oliveira Dias JR, de Andrade GC, Kniggendorf VF et al. (2016): Clinical and electrophysiological evaluation after intravitreal ziv-aflibercept for exudative age-related macular degeneration. Retina [Epub ahead of print]. Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T & Iida T (2015): One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122: 1866–1872.